Member Info for Guy_incognito

And only a week away from b positive keeping his word and never posting here again after he promised to if there wasn’t 7 RNS in May 👍🏻

They’ve recorded a profit once in 25 years and it was before they was even called genedrive.. it’s been huge losses apart from in 2011

If i were to invest, do you think there is more chance of me gaining or losing money - im not using this as financial advice, just interested in what you think is most likely

ChatGPT said:

Understood — you're asking for a probability-based perspective, not financial advice.

Based on the current data and company fundamentals, you are more likely to lose money than gain by investing in Genedrive at this point in time. Here’s why:

🔻 Higher Probability of Loss

Consistent losses: Genedrive has reported multi-year operating and net losses with minimal revenue. That pattern typically signals financial instability.

High burn rate: Negative cash flow suggests the company may need to raise capital again soon, potentially diluting shares.

Stock price trend: A ~57% decline in share price over the last year reflects weak market confidence.

No institutional backing or analyst coverage: This limits both visibility and investor trust.

🔼 What could go right (low probability upside)

Speculative catalyst: If their pharmacogenetic tests (e.g., for stroke patients) gain significant NHS adoption or regulatory traction, it could trigger a rally.

Acquisition or partnership: A biotech partnership or acquisition could offer short-term gains.

Small market cap: At £8M, even modest good news could cause a sharp spike — but it’s speculative.

📊 My Take

Probable outcome: Loss

Possible outcome: Significant gain (but lower likelihood)

This falls squarely into the “high-risk, high-reward” category. If you invest, it's more like betting on a turnaround story than buying into a stable growth company.

Let me know if you want similar breakdowns for more stable or growth-focused biotech stocks.

You said:

so on this basis, if you had money to invest, would you buy stocks in genedrive? answer with yes or no

ChatGPT said:

No.

So I thought I’d join in the fun and ask a simple question

‘ do you think genedrive is a company worth investing in? yes or no’

Investing in Genedrive PLC (LSE: GDR) involves considerable risk due to its current financial and operational status. Here are key points to consider:

📉 Financial Performance

Revenue: For the fiscal year ending June 2024, Genedrive reported revenues of £501,000, a slight increase from £55,000 in 2023, but still modest for a publicly traded company.

Fidelity International

+1

Shares Magazine

+1

Net Losses: The company has consistently reported net losses, with a £7.08 million loss in 2024 and £5.15 million in 2023.

ADVFN

Cash Flow: Operating cash flow remains negative, at -£3.77 million in 2024, indicating ongoing operational challenges.

AJ Bell

+7

Shares Magazine

+7

ADVFN UK

+7

📊 Valuation Metrics

Market Capitalization: Approximately £8.1 million as of April 2025.

Shares Magazine

Price-to-Book Ratio: 2.65, suggesting the stock trades at over twice its book value.

www.alphaspread.com

Price-to-Earnings Ratio: Not applicable due to negative earnings.

🚀 Growth Prospects

Product Development: Genedrive is developing point-of-care pharmacogenetic tests, including the CYP2C19 ID Kit, which has received CE-IVD certification.

Simply Wall St

+2

ADVFN UK

+2

Simply Wall St

+2

Funding: The company secured £1.2 million through the UK Government's Innovation Accelerator programme and an additional £0.5 million R&D tax credit from HMRC.

ADVFN UK

🧠 Analyst Coverage

Currently, there is insufficient analyst coverage to provide reliable forecasts for Genedrive's future growth and revenue.

Simply Wall St

📉 Stock Performance

Share Price: As of May 2025, the stock trades around 1.5p, down approximately 57% over the past year.

ADVFN UK

💬 Investor Sentiment

Investor discussions reflect a mix of cautious optimism and skepticism, with hopes pinned on regulatory approvals and successful product commercialization.

ADVFN UK

Conclusion: Given the company's ongoing financial losses, limited revenue, and lack of analyst coverage, investing in Genedrive PLC is highly speculative. Potential investors should exercise caution and consider the high risks involved.

If you would like information on alternative investment opportunities in the diagnostics sector or other areas, feel free to ask.

Change *

I mean credit to them for being prepared , but up until now it’s always amounted to nothing

It has to charge eventually right 🫣

Every time a sales job is posted people jump the gun and say huge sales are imminent , we’ve been here a million times

You’ve been posting spam there for ages to, so unless you bought in a couple of days ago you are very much in the red there as well

You are deep in the red aren’t you 🫣🤣

It’s like saying why don’t they sell more

Obviously not as straight forward as that

Set up the plasterers table and give out free pens that we can’t afford to give away

You love just making up scenarios

Jimi if I told my managers about my great pipeline having sold naff all i think I’d get laughed out the building

Jimi you’ve been making these promises for a couple of years now

We need b positive to copy and paste that waffle for the 6th time today , that’ll give the SP a quick boost

I’ve no idea how EC and b positive haven’t been banned for spam , it’s just copy and paste the same things all day every day

Everyone else can see this right?

EC , is that your honest opinion?

The more desperate the ramping becomes

Directors bought in at 2.2p in December in case anyone was unaware